The director general leaves his position at the European Federation of Pharmaceutical Industries and Associations (EFPIA) after five years to pursue “a fresh challenge.”
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced that its director general, Richard Bergström, is leaving the post.
“I am proud to leave EFPIA at a time when we have developed policies that promote innovation and patient access, such as through the focus on outcomes and on adaptive pathways to speed up the development of new medicines. After 15 fantastic years leading industry associations in Sweden and in Brussels, it is time for me to take on a fresh challenge,” he said.
Bergström succeeded Brian Ager as director general on April 1, 2011. He was previously director general of LIF, the Swedish research-based pharmaceutical industry association. He is a pharmacist by trade who worked for almost 20 years in the pharmaceutical industry, before moving to LIF in 2002.
Previously Bergström was chair of EFPIA’s Trust Committee and Task Force on Health Technology Assessment and a council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He served on several Swedish government commissions and was vice chairman of the board of the Karolinska Institutet.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.